[{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Manus Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bill & Melinda Gates Foundation","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Catabasis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"CAT-5571","moa":"Autophagy","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VIR-1111","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Atreca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"ATRC-501","moa":"||CSP","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Inflammasome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"OPC-167832","moa":"||Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"OPC-167832","moa":"||Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bill & Melinda Gates Foundation \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ GSK"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Delamanid","moa":"||Mycobacterium tuberculosis H37Rv","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Delamanid","moa":"Mycobacterium tuberculosis H37Rv","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Osivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Insud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Hormone","year":"2024","type":"Funding","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Expanded Collaboration","leadProduct":"Medroxyprogesterone Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"MedinCell","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Hormone","year":"2022","type":"Funding","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"SK Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Funding","leadProduct":"AR-701","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Ethris","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"PopVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Providence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Gritstone bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Self-Amplifying Mrna Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Icosavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"IVX-411","moa":"SARS-CoV-2 S protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Funding","leadProduct":"Ferrous Gluconate","moa":"||Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"AS01E","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0.55000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.55000000000000004,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bill & Melinda Gates Foundation","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Funding","leadProduct":"DARE-LBT","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"VitriVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Hexavalent Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Inventprise","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"IVT-25","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Immorna","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"JCXH-108","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacilli Paracasei","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Micron Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"Measles And Rubella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vaxxas","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Measles Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"MK-7762","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"nOPV2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"11","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"nOPV2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"11","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"nOPV2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"11","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Poliomyelitis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Quadrivalent Human Papillomavirus (Serotypes 6, 11, 16 and 18) Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"The Wistar Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"RA 27\/3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 rS Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Smart Immune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"VIR-1388","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vaxart","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"VXA-G1.1-NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"DelSiTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Relation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Chemify","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"SpyBiotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Nuvisan GmbH","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"SNIPR Biome","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bactolife","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Aegis Life","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"VitriVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Tessera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Aegis Life","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Radiant Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Matrix-M","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Sail Biomedicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Radiant Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Phase Genomics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Atomwise","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Surf Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Replay Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"}]
Find Clinical Drug Pipeline Developments & Deals by Bill & Melinda Gates Foundation
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
